BioPharma Dive9h
Galapagos, after research struggles, will split in two and revamp Gilead deal
Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...
Gilead Sciences Inc. stock outperforms competitors despite losses on the day
This was the stock's fifth consecutive day of losses.
FierceBiotech1d
Galapagos splits in 2, laying off 40% of staff, shrinking pipeline and ending Gilead partnership
After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...
STAT1d
Galapagos to split itself into two companies as part of turnaround plan
The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...
MM&M18h
Galapagos to split itself into two companies, lay off 40% of staff
Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...
bovnews19h
BofA Securities Just Resumed Gilead Sciences Inc (GILD) Stock—What Does This Mean for Investors?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors
This was the stock's fourth consecutive day of losses.
Christianity Today1d
The Balm of Gilead Grows Again, Maybe
And other news from Christians around the world.
Here’s Why TCW Relative Value Large Cap Fund Exited its Position in Gilead Sciences (GILD)
TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...
Gilead price target lowered to $83 from $84 at RBC Capital
RBC Capital analyst Brian Abrahams lowered the firm’s price target on Gilead (GILD) to $83 from $84 and keeps a Sector Perform rating on the ...
Irish Independent on MSN2d
Gilead gives its blessing to Poolbeg Pharma’s Hookpia merger deal
US biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...